 SHANGHAI, China and PLANEGGMUNICH, Germany, Jan. 25, 2021 PRNewswire -- I-Mab Nasdaq: IMAB, and MorphoSys FSE: MOR; Prime Standard Segment, MDAX TecDAX; NASDAQ: MOR today announced that the first patient has been dosed in a phase 1 dose escalation study to evaluate the safety,... 